Methods for detection and treatment of cancers

By targeting LY6C and phosphorylated ANXA2 proteins with nanobodies and photoimmunotherapy, or using inhibitors and decoys, cancer detection and treatment methods are enhanced, addressing the limitations of current therapies and improving survival rates.

WO2026136325A2PCT designated stage Publication Date: 2026-06-25SENTRIMED INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
SENTRIMED INC
Filing Date
2025-12-16
Publication Date
2026-06-25

AI Technical Summary

Technical Problem

Current cancer treatments have limited effectiveness, with a 5-year survival rate stagnating at around 50% and significant mortality rates, necessitating a better understanding of molecular pathways driving cancer progression.

Method used

Targeting LY6C and phosphorylated ANXA2 proteins using anti-LY6C protein nanobodies and fluorescent dyes for photoimmunotherapy, or employing inhibitors and decoys to modulate ANXA2 phosphorylation, to detect and treat cancers such as carcinoma, leukemia, and other types.

Benefits of technology

Enhances cancer detection and treatment efficacy by specifically targeting key proteins, potentially improving survival rates and treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000024_0000
    Figure 00000024_0000
  • Figure 00000024_0001
    Figure 00000024_0001
  • Figure 00000025_0000
    Figure 00000025_0000
Patent Text Reader

Abstract

Disclosed are methods for detecting and treating cancers (such as carcinoma, leukemia, lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, oral cancer, prostate cancer and / or breast cancer). The method may include receiving a sample from a patient (such as a sample from a biopsy, a sample from an extracellular vesicle, or a sample from a circulating tumor cell). The method may include determining whether a LY6C protein or a phosphorylated ANXA2 protein is detected in the sample. The method may include treating a patient for cancer by targeting the LY6C protein when the LY6C protein is detected (e.g., using photoimmunotherapy (PIT) or near infrared photoimmunotherapy (NIR-PIT)). or treating a patient for cancer by targeting an ANXA2 protein (e.g, using inhibitors, decoys, etc.) when the phosphorylated ANXA2 protein is detected.
Need to check novelty before this filing date? Find Prior Art